BIOMAT Database Logo BIOMAT Database Logo

A double-blind, placebo-controlled trial of topical I,25-dihydroxycholecalciferol in psoriasis. 1989

C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Department of Dermatology, York District Hospital, U.K.

In a double-blind trial of topical I,25-dihydroxycholecalciferol in 47 patients with psoriasis no benefit was shown compared with placebo.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations

Related Publications

C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis.
February 1988, Lancet (London, England),
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Inefficacy of topical thyroid hormone analogue TriAc in plaque psoriasis: results of a double-blind placebo-controlled trial.
August 2004, The British journal of dermatology,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Topical insulin in wound healing: a randomised, double-blind, placebo-controlled trial.
November 1999, Journal of wound care,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis.
June 1991, The British journal of dermatology,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis.
October 1989, Journal of the American Academy of Dermatology,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Topical mitomycin application after laryngotracheal reconstruction: a randomized, double-blind, placebo-controlled trial.
October 2001, Archives of otolaryngology--head & neck surgery,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study.
August 2007, The British journal of dermatology,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
September 2013, The Journal of arthroplasty,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
A double-blind study of topical 1 alpha,25-dihydroxyvitamin D3 in psoriasis.
May 1989, The British journal of dermatology,
C A Henderson, and J Papworth-Smith, and W J Cunliffe, and A S Highet, and H K Shamy, and B M Czarnetzki
Topical pentoxifylline for pressure ulcer treatment: a randomised, double-blind, placebo-controlled clinical trial.
August 2018, Journal of wound care,
Copied contents to your clipboard!